everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...4445464748495051525354...132133»
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Journal:  Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant. (Pubmed Central) -  Jul 31, 2021   
    Background: Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, may be efficacious in preserving renal function in liver transplantation (LT) recipients while preventing hepatocellular carcinoma (HCC) recurrence...mTOR inhibitors were safely administered without serious adverse events that led to drug discontinuation. We demonstrated that patients with renal impairment showed significant improvement in renal function regardless of the timing of mTOR inhibitor start, suggesting that switch to mTOR inhibitors may be beneficial when renal function declines.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors. (Pubmed Central) -  Jul 31, 2021   
    Remarkably, we found that auranofin (AF) combined with everolimus significantly suppressed tumor growth in HCT116 and SGC-7901 xenograft models with no significant signs of toxicity. Our findings identify a promising therapeutic combination for cancer and has important implications for developing mTOR inhibitor-based combination treatments.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Local Administration of Targeted Liposomes Loaded with Everolimus for Interstitial Lung Disease in Systemic Sclerosis (Channel 5) -  Jul 29, 2021 - Abstract #ERS2021ERS_4604;    
    Tracheal instillation of LIP(ev)-HA400kDa in mouse model of SSc-ILD significantly decreased of interstitial inflammation grade, also decreased interstitial and peribronchial fibrosis respect to untreated mice. Results demonstrate that local administration of everolimus by liposomes is an effective option to interfere with lung fibrogenesis limiting systemic toxicity in particular in SSc patients where a complex therapeutic regimen is usually required.
  • ||||||||||  sirolimus / Generic mfg.
    [VIRTUAL] Lymphangioleiomyomatosis – experience of a university hospital () -  Jul 29, 2021 - Abstract #ERS2021ERS_3291;    
    Conclusion TSC-LAM patients were younger and had more extrapulmonary features, but mortality was higher in S-LAM group. Almost half the patients had lung function impairment, showing high morbidity of LAM.
  • ||||||||||  Xience (everolimus-eluting stent) / Abbott
    Journal:  Intracellular glutamine level determines vascular smooth muscle cell-derived thrombogenicity. (Pubmed Central) -  Jul 29, 2021   
    Intracellular glutamine level is likely to determine vascular SMC-related thrombogenicity regardless of mTOR pathway activity. Therefore, increased intracellular glutamine level might contribute partially to the beneficial effect of EES use on stent thrombosis.
  • ||||||||||  everolimus / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Preclinical, Journal, Combination therapy:  Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231. (Pubmed Central) -  Jul 28, 2021   
    Therefore, increased intracellular glutamine level might contribute partially to the beneficial effect of EES use on stent thrombosis. Everolimus can enhance the effect of paclitaxel on MDA-MB-231/ADR cells, inhibit cell proliferation, induce apoptosis and arrest cell cycle in the G1 phase mainly by down-regulating the expressions of key proteins in the mTOR signaling pathway.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Developments in immunosuppression. (Pubmed Central) -  Jul 28, 2021   
    Everolimus can enhance the effect of paclitaxel on MDA-MB-231/ADR cells, inhibit cell proliferation, induce apoptosis and arrest cell cycle in the G1 phase mainly by down-regulating the expressions of key proteins in the mTOR signaling pathway. Recent knowledge creates a path towards future immunosuppression success in sensitized recipients and in those in high risk of viral infections or CNI nephrotoxicity.
  • ||||||||||  Zanosar (streptozocin) / Teva
    Journal:  Spontaneous intra-abdominal hemorrhage of a well-differentiated, grade 3 gastric neuroendocrine tumor during drug-based treatment. (Pubmed Central) -  Jul 28, 2021   
    A clinical diagnosis of NET G3 with multiple liver metastases was given, after which everolimus was administered in combination with a somatostatin analogue...Although the patient was treated with streptozocin, abdominal CT indicated progression of the liver metastases...To the best of our knowledge, this is the first case of a patient who developed spontaneous hemoperitoneum during drug treatment for a NET G3 to be reported in the English literature. It is essential that additional data be obtained to determine the optimal treatment for this disease.
  • ||||||||||  everolimus / Generic mfg.
    Biomarker, Journal:  New Insights into Red Blood Cell Microcytosis upon mTOR Inhibitor Administration. (Pubmed Central) -  Jul 28, 2021   
    The aim of this study was to evaluate the effect of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, on red blood cell parameters in the context of iron homeostasis in patients with tuberous sclerosis complex (TSC) and evaluate its effect on cell size in vitro...This effect is not clearly related to a deficit of iron and erythroid maturation. This observation confirms that mTOR signaling plays a complex role in the control of cell size.
  • ||||||||||  fulvestrant / Generic mfg.
    Journal:  Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer. (Pubmed Central) -  Jul 28, 2021   
    AMPK is a major negative regulator of mTOR, and to our knowledge, this is the first study on the contribution of AMPK-dependent regulation of mTOR by ERα. Furthermore, the studies revealed that independent of the p53 mutation status, combination of Fulvestrant and Everolimus may be a viable first line therapeutic strategy for potentially delaying resistance of ERα+/HER2- LBC to ET.
  • ||||||||||  entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
    Clinical, Journal:  Drug repositioning based on network-specific core genes identifies potential drugs for the treatment of autism spectrum disorder in children. (Pubmed Central) -  Jul 27, 2021   
    We found a total of 42 candidate drugs that were associated with mental illness, among which 10 drugs (baclofen, sulpiride, estradiol, entinostat, everolimus, fluvoxamine, curcumin, calcitriol, metronidazole, and zinc) were postulated to be associated with ASD. This study proposes a powerful network-based drug repositioning framework and also provides candidate drugs as well as potential drug targets for the subsequent development of ASD therapeutic drugs.
  • ||||||||||  docetaxel / Generic mfg.
    [VIRTUAL] An automated platform for rapid drug screening in patient-derived micro-organospheres () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_2442;    
    Our microfluidic-based, patient-derived MOS assay, provides a rapid, scalable, and cost-effective platform to study drug sensitivity. This technology has the potential to be used for both diagnostics to guide patient treatment and as a screening platform for new breast cancer drug discovery.
  • ||||||||||  Nulojix (belatacept) / BMS
    Clinical, Journal:  THIRTY YEARS OF TACROLIMUS IN CLINICAL PRACTICE. (Pubmed Central) -  Jul 22, 2021   
    Current understanding of the role of tacrolimus focuses more on its efficacy in preventing graft rejection and graft loss. As we enter the fourth decade of tacrolimus use, newer studies utilizing of novel combinations (as with the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and T-cell co-stimulation blockade with belatacept) offer potential for enhanced benefits.
  • ||||||||||  Trial completion date, Trial primary completion date, Combination therapy:  ENCERT: Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov) -  Jul 21, 2021   
    P1,  N=15, Recruiting, 
    As we enter the fourth decade of tacrolimus use, newer studies utilizing of novel combinations (as with the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and T-cell co-stimulation blockade with belatacept) offer potential for enhanced benefits. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  temozolomide / Generic mfg.
    Review, Journal, IO biomarker:  How I treat neuroendocrine tumours. (Pubmed Central) -  Jul 21, 2021   
    However, this new entity also poses a therapeutic challenge as only limited data are currently available. The present article aims to provide an overview on our personal treatment concepts for advanced NETs with a focus on tumours of gastroenteropancreatic origin.
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (clinicaltrials.gov) -  Jul 15, 2021   
    P1/2,  N=86, Completed, 
    This method has been used for many years clinically to support patient care. Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jul 2021 | Trial primary completion date: Jun 2021 --> Oct 2020